ANDA 40768, held by Accord Healthcare. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 40768 (Methotrexate Sodium Preservative Free), held by Accord Healthcare, was first approved by FDA on Apr 30, 2007, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate Sodium Preservative FreeEQ 250MG BASE/10ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
| Jan 14, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jan 14, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Aug 16, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 7, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 16, 2012 | Supplement 5Labeling | Approved | None posted |
| Apr 30, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters